^
    almost3years
    #asco21 5508: #TAPUR study of pertuzumab + trastuzumab in uterine cancer w/ ERBB2 amplification, overexpression, or mutation (+ one with ERBB3 amplification). Evidence of anti-tumor activity in heavily pre-treated pts. (@jrgralow)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • ERBB3 mutation • ERBB3 amplification
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost3years
    Will be presenting on behalf of the TAPUR study group - Pertuzumab plus trastuzumab for uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation. See you virtually #ASCO21 on 6/7 Mon 9:45am ET! @ASCO @CancerCenter @Integrativeonc (@eugeneahn)
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 overexpression • HER-2 amplification • ERBB3 mutation • ERBB3 amplification
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)